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Objective: Traditionally integrated coronary artery revascularization has been
described as a 2-stage procedure. We evaluated the safety and feasibility of 1-stage,
simultaneous, hybrid, robotically assisted coronary artery bypass grafting surgery
and percutaneous coronary intervention.
Methods: Fifty-eight patients underwent simultaneous, integrated coronary artery re-
vascularization in an operating theater equipped with angiographic equipment. Forty-
five patients were men. The mean age was 59 years. All internal thoracic arteries were
harvested with robotic assistance. All anastomoses were manually constructed
through a small anterior non–rib-spreading incision without cardiopulmonary bypass
on the beating heart. Immediately after and within the same operative suite, both an-
giographic confirmation of graft patency and percutaneous coronary intervention
were performed. In 52 patients therapeutic anticoagulation was achieved with the
direct thrombin inhibitor bivalirudin.
Results: There were no deaths or wound infections. There was 1 perioperative myo-
cardial infarction. One patient had a stroke, and 3 patients required re-exploration for
bleeding. The median lengths of intensive care and hospital stay were 1 and 4 days,
respectively. All patients were alive and symptom free at follow-up (mean, 20.2
months; range, 1.1–40.8 months). Long-term angiographic follow-up in 54 patients
showed 49 (91%) patent grafts (mean, 9.0 months; range, 4.3–40.8 months). There
were 7 in-stent restenoses and 2 occluded stents.
Conclusion: For multivessel coronary artery disease, simultaneous integrated coro-
nary artery revascularization with bivalirudin is safe and feasible. This approach
enables complete multivessel revascularization with decreased surgical trauma and
postoperative morbidity. Further studies are necessary to better determine patient
selection and long-term outcomes.
T
reatment options for multivessel coronary artery disease are in a state of flux,
with significant advancements in both minimally invasive coronary surgery
and percutaneous coronary intervention (PCI). As interventional cardiologists
become more aggressive with drug-eluting stent (DES) technology and cardiac sur-
geons pursue less invasive surgical techniques, the potential complimentary aspects
of these 2 revascularization strategies become seemingly more evident. Surgical re-
vascularization confers the survival benefit of the left internal thoracic artery
(LITA) to left anterior descending coronary artery (LAD) graft.1 Moreover, when
faced with significant stenosis of non-LAD coronary vessels, PCI with DESs provides
an acceptable alternative to radial artery and saphenous vein grafts, with recognition
that follow-up for DESs has only been for a short duration.2-4 The disadvantage of PCI
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ETAbbreviations and Acronyms
ACT 5 activated clotting time
ASA 5 acetylsalicylic acid
BMS 5 bare-metal stent
CABG 5 coronary artery bypass grafting
DES 5 drug-eluting stent
endoACAB 5 endoscopic atraumatic coronary
artery bypass
ICR 5 integrated coronary revascularization
ICS 5 intercostal space
ICU 5 intensive care unit
LAD 5 left anterior descending coronary artery
LITA 5 left internal thoracic artery
PCI 5 percutaneous coronary intervention
TIMI 5 Thrombolysis In Myocardial Infarction
centers on ostial and complex lesions of the LAD, with an
increased need for reintervention.5-7 Thus far, PCI has been
inferior to surgical revascularization when faced with LAD
disease and has yet to demonstrate a survival benefit.1,5
With this paradox, hybrid or integrated coronary revascu-
larization (ICR) has evolved as an alternative therapy for mul-
tivessel coronary artery disease, combining aspects of both
the interventional and surgical approaches into a single proce-
dure.8 ICR combinesminimally invasive LITA to LAD revas-
cularizationwith PCI of the remaining flow, limiting coronary
lesions. Integrating the 2 procedures into one therapeutic mo-
dality aims to provide the patient with the beneficial aspects of
each successive technique in the least invasive way possible.
Still, the theoretic benefits of ICR have largely been over-
shadowed by logistic challenges inherent to its use and chal-
lenges with respect to differing anticoagulation regimens
used for surgical coronary revascularization and PCI. Coro-
nary artery bypass grafting (CABG) surgery and PCI neces-
sitate effective coordination of an operating room and
a catheterization laboratory, respectively. For this reason,
ICR has been largely confined to a 2-staged procedure. Sur-
gical revascularization is typically performed first, followed
by PCI of the remaining stenosed arteries several hours,
days, or weeks later.9-11 Having to routinely accommodate
both an operating room and an interventional laboratory
has prevented the widespread acceptance of ICR. One solu-
tion is to incorporate the 2 techniques into a single simulta-
neous procedure using an enhanced operating theater
with angiographic equipment,12 permitting a truly hybrid
approach to multivessel coronary artery disease. Although
previously conceptualized in the literature, the discordance
in anticoagulation protocols for CABG surgery and PCI, to-
gether with a lack of infrastructure,13 has prevented simulta-
neous ICR from reaching full fruition. Recently, an enhanced
operating theater was constructed at our institution (Figure 1).
Moreover, in an effort to develop a unifying anticoagulationThe Journal of Thoregimen suitable to both CABG and PCI, we evaluated the
use of bivalirudin (The Medicines Company, Parsippany,
NJ) as the sole anticoagulant during simultaneous ICR.
Our group and others have reported independently first
case experiences with robotically assisted simultaneous
ICR.12,14,15 With the hypothesis that ICR performed simulta-
neously in an enhanced operative suitewith bivalirudinwould
be associated with excellent early and intermediate-term out-
comes, we report the experience from our initial case series.
Materials and Methods
Patient Population
Between September 2004 and July 2007, after obtaining ethics
approval and each patient’s fully informed written consent, 65
consecutive patients underwent ICR. The first 5 patients had ICR
as a 2-staged approach because of the learning curve required to fa-
miliarize the team with combined procedures in an enhanced hybrid
operative suite. The remaining 60 patients underwent simultaneous
ICR. All patients had a preoperative computed tomographic scan of
the thorax and pulmonary function tests. Acetylsalicylic acid (ASA)
was routinely discontinued 7 days before the operation.
Patient history, physical findings, and angiograms were re-
viewed by all members of the ICR team (the cardiac surgeon, inter-
ventional cardiologists, and cardiac anesthesiologists). Selection
criteria included patients with double- or triple-vessel disease in
whom the LAD lesion was not suitable for PCI but suitable for
surgical revascularization and in whom the non-LAD lesions were
amenable to PCI. Exclusion criteria consisted of patients with con-
traindications to robotically assisted endoscopic atraumatic coro-
nary artery bypass (endoACAB) surgery or contraindications to
PCI of non-LAD lesions (Table 1).
The sequence and approach to ICR involved initial robotically as-
sisted endoACAB grafting of the LITA graft to the LAD on the beat-
ing heart. This was followed immediately by PCI of the non-LAD
stenotic coronary artery lesions in the same enhanced hybrid opera-
tive suite. Preoperative patient demographics are shown in Table 2.
Surgical Procedure
The detailed surgical technique of robotically assisted endoACAB
has been previously described.12,16 Briefly, using robotic assistance
the LITA was harvested endoscopically, and a vertical pericardiot-
omy was performed. The LAD was identified, and the intercostal
space (ICS) best suited for direct access was determined. After
achieving appropriate anticoagulation (activated clotting time
[ACT] .300 seconds), the LITA graft was clipped and cut. Stabili-
zation of the LAD was achieved with the Octopus TE stabilizer
(Medtronic, Minneapolis, Minn) inserted through a port in the third
ICS. The LITA was manually anastomosed to the LAD on the beat-
ing heart through a small non–rib-spreading incision. Intracoronary
shunts were used in all patients. LITA graft flow was immediately
assessed by using transit-time Doppler scanning (Medi-stem AS,
Medtronic).
Anticoagulation Protocol
In the first 6 patients anticoagulation for the entire procedure
was achieved with an intravenous bolus dose of heparin (400 IU/
kg). One patient received both an intravenous bolus of heparinracic and Cardiovascular Surgery c Volume 136, Number 3 703
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ET(400 IU/kg) for surgical revascularization and bivalirudin at an intra-
venous bolus of 0.75mg/kg followed by an infusion of bivalirudin at
1.75 mg $ kg21 $ h21 for PCI. The remaining 51 patients received
bivalirudin alone (intravenous bolus dose of 0.7 5 mg/kg followed
Figure 1. Enhanced operating theater for simultaneous integrated
coronary revascularization, depicting the orientation of the carbon
fiber operating table, digital C-arm, and daVinci telemanipulation
system in relation to one another. Display monitors in the
background move to a central position to facilitate angiographic
imaging.
TABLE 1. Integrated coronary revascularization inclusion
and exclusion criteria
Exclusion criteria
1. Contraindications to endoACAB
i) Nongraftable LAD
ii) Buried intramyocardial LAD
iii) Inadequate intrathoracic cavity space on thorax CT
iv) Inability to undergo off-pump beating heart
revascularization
v) Previous operation involving the left chest cavity
vi) History of left subclavian artery and LITA stenosis
vii) FEV1 ,50%
viii) BMI .40 kg/m2
2. Contraindications to percutaneous coronary intervention
i) Peripheral vascular disease precluding vascular access
ii) Vessel size ,2.0 mm
iii) Tortuous calcified vessels believed to preclude stent
placement
iv) Fresh thrombotic lesion
v) Chronic totally occluded vessels
vi) Serum creatinine $200 mmol/L
endoACAB, Atraumatic coronary artery bypass; LAD, left anterior descend-
ing; CT, computed tomogram; LITA, left internal thoracic artery; FEV1, forced
expiratory volume in 1 second; BMI, body mass index.704 The Journal of Thoracic and Cardiovascular Surgery c Sepby an infusion of 1.75 mg $ kg21 $ h21) for the entire hybrid proce-
dure (surgical revascularization and PCI). In all patients who
received heparin, this was reversed with protamine sulfate on
successful completion of the LITA–LAD anastomosis. For the
PCI, an additional heparin bolus was given that was not reversed.
In the patients receiving a bivalirudin infusion, the infusion was con-
tinued at the same rate of 1.75 mg $ kg21 $ h21 until PCI was com-
pleted and the patient was transferred to the intensive care unit
(ICU). Throughout the procedure, anticoagulation was monitored
by means of frequent ACT measurements to maintain an ACT of
greater than 300 seconds. A further half bolus of bivalirudin
(0.375 mg/kg) was administered to enhance the ACT, if necessary.
Percutaneous Intervention
Immediately after the surgical revascularization, with all incisions
closed, the operating room was transformed for PCI. The floor-
mounted C-arm was brought into position, and the display monitors
were brought to the center of the operating table. By using femoral
access, angiographic confirmation of LITA–LAD patency was
verified. PCI of all non-LAD coronary lesions was performed
with Taxus (Boston Scientific, Boston, Mass) and Cypher (Johnson
& Johnson, Cincinnati, Ohio) DESs or Cobalt Chromium
Driver (Medtronic) bare-metal stents (BMSs). On PCI completion,
while still on a bivalirudin infusion, 600 mg of clopidogrel was
TABLE 2. Patient demographics
Profile n 5 60 (%)
Mean age (y) 59.9 6 11.7
Sex
Male 47 (78%)
Female 13 (22%)
LV grade
I 45 (75%)
II 12 (20%)
III 3 (6.0%)
IV 0
CCS functional class
I 0
II 6 (10%)
III 34 (56%)
IVa 16 (27%)
IVb 3 (5%)
IVc 1 (2%)
Recent MI 10 (17%)
Stroke 2 (3.3%)
PVD 0
COPD 2 (3.3%)
Diabetes 14 (23%)
Preoperative creatinine
#120 54 (90%)
121–180 5 (8.3%)
$180 1 (1.7%)
BMI .30 kg/m2 24 (40%)
LV, Left ventricle; CCS, Canadian Cardiovascular Society; MI, myocardial
infarction; PVD, peripheral vascular disease; COPD, chronic obstructive
pulmonary disease; BMI, body mass index.tember 2008
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pidogrel once daily. Eighty-one milligrams of ASA was adminis-
tered through a nasogastric tube 6 hours after the operation, and
then 81 mg was administered once daily. The femoral arterial
sheaths were removed 90 minutes after the discontinuation of biva-
lirudin.
Results
Intraoperative Results
Fifty-nine patients had double-vessel and 1 patient had triple-
vessel coronary artery disease. Of the 60 patients, 58 (97%)
had successful simultaneous ICR. Two patients sustained
TABLE 3. Technical information for percutaneous coronary
intervention
Total patient no. 58
Total lesion no. 59*
Target vessel
RCA: 21
Circumflex: 22
Diagonal: 16
Stent type
Drug-eluting stents: 53
Taxus: 49
Cypher: 3
Endeavor: 1
Bare-metal stents: 6
Cobalt Chromium (Driver): 6
Stents per lesion
1: 54
2: 4
3: 1
Stent diameter
,3 mm: 26
$3 mm: 33
Length of vessel stented
8.0–12.0 mm: 22
15.0–20.0 mm: 27
20.1–30.0 mm: 7
.30.0 mm: 3
Lesion type
A/B1: 31
B2/C: 28
Predilatation
Lesion predilated: 34
Lesion not predilated: 25
Postdilatation
Postdilated: 8
Not postdilated: 51
Angiographic success
,20% residual stenosis: 43
$20% residual stenosis: 14
Stent underexpansion: 8
Incomplete lesion coverage: 6
RCA, Right coronary artery. *One patient had stenting of both the right cor-
onary and circumflex arteries.The Journal of Thoventricular fibrillation during the beating heart LITA–LAD
anastomosis, necessitating defibrillation, which was success-
ful, followed by conversion to sternotomy. Both of these
patients underwent complete surgical revascularization off-
pump through a sternotomy incision by using bivalirudin
for anticoagulation and had uncomplicated postoperative
courses. Twenty-one patients had PCI to the right coronary
artery, 22 patients had PCI to the circumflex artery, and an
additional 16 patients had PCI to the first diagonal branch.
Detailed technical information of the stenting procedures
are provided in Table 3. Intraoperative angiographic analysis
confirmed LITA–LAD patency of grade A by means of Fitz-
gibbons criteria17 in 54 (93%) of 58 patients. In the 4 remain-
ing patients 2 patients had Thrombolysis In Myocardial
Infarction (TIMI) flow 1, and 2 patients had TIMI flow
0 into the LAD. One of the 2 patients with TIMI flow
0 had a chronically occluded LAD preoperatively with very
poor collateral flow. Intraoperatively, this patient was found
to have a diffusely diseased LAD with a 1.0-mm lumen
not very suitable for surgical revascularization. Attempt at
revascularization with LITA–LAD anastomoses was made,
knowing there would be very poor runoff. Intraoperative an-
giographic analysis confirmed an occluded anastomosis. The
other patient with TIMI flow 0 also had an occluded LAD
with collaterals to a small distal LAD segment. A small
LADwas confirmed in the operating room. Intraoperative an-
giographic analysis showed a patent LITA–LAD anastomo-
sis with retrograde flow but no antegrade flow. Because the
distal LAD was a small-caliber vessel, the chance of improv-
ing this anastomosis was very low; hence this anastomosis
was not further revised. Interestingly, this patient had a Fitz-
gibbons A LITA–LAD anastomosis at long-term follow-up.
Perioperative Results
Median postoperative length of hospital stay was 4 days
(range, 3–9 days). Fifty-five (95%) patients were transferred
to the ward from the ICU within 12 hours. Two patients were
in the ICU for 2 days, and 1 patient was in the ICU for 3 days.
Re-exploration for bleeding was the cause of the extended
ICU stay in all 3 patients (Table 4). A surgical source of
TABLE 4. Postoperative events
Average 6 SD Median
Total procedure time (min) 205 6 39 217
Length of stay in ICU (d) 1.1 6 0.43 1
Length of hospital stay (d) 4.3 6 1.42 4
24-h Chest tube drainage (mL) 809 6 724 613
Hemoglobin level at discharge (g/L) 110 (range, 74–133) 109
Neurologic complication 1 patient –
Perioperative myocardial infarction 1 patient –
Reoperation for bleeding 3 patients –
ICU, Intensive care unit.racic and Cardiovascular Surgery c Volume 136, Number 3 705
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covered at the camera port site of the fifth ICS. Although ini-
tial re-exploration was thoracoscopic, extensive thrombus
causing poor visibility necessitated access through the origi-
nal minithoracotomy, whereby bleeding was then success-
fully controlled. The other 2 patients were coagulopathic,
and a bleeding site was never identified. Because of inade-
quate exposure and to safely rule out a surgical bleed, after
inspection thoracoscopically and directly through the original
minithoracotomy, conversion to sternotomy was necessary.
Blood transfusions, including packed red blood cells, fresh
frozen plasma, and platelets, were required in these 3 patients
in addition to 6 other patients.
There were no deaths. One patient had a small postopera-
tive stroke with no clinically significant sequelae. One patient
was given a diagnosis of perioperative myocardial infarction
evidenced by a new Q-wave in his inferior leads on the post-
operative electrocardiogram (Table 4). This individual, who
had received heparin and bivalirudin for PCI of the right cor-
onary artery, required re-exploration and conversion to ster-
notomy for bleeding and received fresh frozen plasma and
platelets.
Follow-up
At a mean follow-up of 20.2 months (range, 1.1–40.8
months), all 58 patients reported Canadian Cardiovascular
Society Class 0 angina. Fifty-four (93%) patients have since
returned for long-term angiographic follow-up (mean, 9.0
months; range, 4.3–40.8months). Two patientswere not reca-
theterized for medical reasons (renal insufficiency and a peri-
operative stroke), and 2 patients declined recatheterization.
The LITA graft was patent in 49 (91%) of 54 patients, and 1
LITA graft was atretic. By using Fitzgibbons angiographic
grading criteria,17 the LITA was grade A in 36 patients and
grade B in 13 patients. Of the patients with a score of grade
B, 8 patients had TIMI flow 3, and 5 patients had TIMI flow
1. One patient with TIMI flow 1 had PCI of the anastomosis
with a BMS, even though he was asymptomatic. Another
patient with TIMI flow 1, also asymptomatic, had PCI of
the native LAD with a DES. One patient’s LITA could not
be cannulated, and the anastomosis could not be properly
visualized to confirm patency. This LITA was very small
during intraoperative angiographic analysis and had become
atretic by the long-term angiographic assessment because of
competitive flow from the collateral circulation to the LAD.
In the 5 patients whose LITA grafts were not patent, all
were asymptomatic. One patient had the previously discussed
chronically occluded LAD with the diffusely diseased vessel
(1.0-mm lumen) and TIMI flow 0 at the time of intraoperative
angiography. In the 4 remaining patients 2 LITA grafts had
evidence of a string sign, 1 had TIMI flow 0 into the LAD,
and 1 did not have antegrade flow into the LAD (TIMI flow
0) but had prompt retrograde flow. These 4 patients had patent
grafts at intraoperative angiographic analysis.706 The Journal of Thoracic and Cardiovascular Surgery c SepThere were 2 occluded stents. In addition, 8 vessels had
in-segment stenosis, of which 7 had binary in-segment reste-
nosis and 1 had in-segment stenosis noted on preoperative
angiographic assessment and initially judged not to require
intervention; however, this vessel was stenosed 50% or
greater at 6-month follow-up. Of the 7 patients with in-
segment binary restenosis, 2 underwent target lesion revascu-
larization with repeat PCI of the stented vessel using a DES.
Of note, 5 of these patients underwent a suboptimal stenting
procedure ($20% residual stenosis), and 2 of these patients
initially had undergone a BMS insertion (Table 3). Of the
53 inserted DESs, 2 were occluded, and 5 had in-segment bi-
nary restenosis. The 9 patients with stent complications were
all completely asymptomatic and continued to report Cana-
dian Cardiovascular Society Class 0 angina.
Discussion
The present study demonstrates simultaneous ICR in a single
operative sequence for multivessel coronary artery disease to
be safe, efficacious, and reproducible. Angelini and col-
leagues8 were the first to describe ICR. This consisted of 6
patients, 4 of whom had a 2-stage procedure and 2 of
whom underwent simultaneous ICR with a standard catheter-
ization laboratory. Minimally invasive direct coronary artery
bypass surgery was used in Angelini and colleagues’ series,
whereby the LITA graft was harvested and anastomosed to
the LAD directly through an anterior thoracotomy on the
beating heart. Minimally invasive direct coronary artery by-
pass has since fallen out of favor with most surgeons because
of the technical challenges of direct LITA harvesting and the
morbidity associated with costochondral dislocation and rib
fractures.18 With the development of computer-enhanced
telesurgical systems, minimally invasive surgical coronary
artery revascularization has become more feasible.19 More-
over, with the introduction of DESs and the potential for
lower rates of in-stent restenosis,4 ICR might become
a more acceptable alternative for revascularization in select
patients with multivessel coronary artery disease. To date,
the majority of ICR cases have been performed through
a 2-stage approach. The few cases that have been performed
with robotic assistance or simultaneously in a 1-stage
approach have been performed on the arrested heart with
cardiopulmonary bypass.14,20,21 We believe the maximal
benefit of ICR to be achieved when surgical revascularization
is performed with a minimal-access, off-pump, beating heart
technique followed by immediate PCI in the same operating
theater.
ICR eliminates the need for sternal incisions and the need
for cardiopulmonary bypass, while still providing the sur-
vival benefit of the LITA–LAD anastomosis and, with the
addition of PCI, ensures complete revascularization of all sig-
nificantly diseased arteries. The avoidance of cardiopulmo-
nary bypass provides certain advantages, mainly reduced
ventilation times, ICU and hospital lengths of stay, andtember 2008
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addition, although evidence continues to be conflicting, it
has been suggested that beating heart surgery might be asso-
ciated with lower mortality and major adverse events.23
Moreover, simultaneous ICR provides a practical 1-stage
procedure that is efficient and convenient for the surgeon,
the interventional cardiologist, and, most importantly, the pa-
tient. It has been suggested that ICR is best performed as a 2-
stage procedure and that the use of a single revascularization
suite is ‘‘suboptimal.’’10 It is our contention that the 1-stage
approach is a safer and more efficient alternative. With the
2-stage approach to ICR, the patient remains incompletely
revascularized and at risk for a cardiovascular event for an
extended period of time. Simultaneous ICR reduces this
concern. The 1-stage approach also optimizes continuity of
care through direct intraoperative collaboration among the
surgeon, cardiologist, and cardiac anesthesiologist. Also,
with the inevitable increase in hospital length of stay and re-
source use to coordinate a 2-staged procedure, simultaneous
ICR has the potential to be more cost-effective in the long
term. Finally, the effect on patient psyche and satisfaction
from having to undergo only 1 procedure as opposed to 2 pro-
cedures is likely significant and should not be overlooked.
Simultaneous ICR presents the additional challenge of
combining 2 procedures that have different anticoagulation
requirements. Overlapping these 2 anticoagulation regimens
increases the risk of perioperative hemorrhage. After careful
study, bivalirudin was deemed to be an appropriate pharma-
cologic agent for the entire hybrid procedure. Bivalirudin has
been proved both safe and effective as an anticoagulant in pa-
tients with unstable angina undergoing PCI.24,25 Although
there is less experience with bivalirudin in cardiac surgery,
recent data suggest bivalirudin to be a clinically feasible alter-
native to heparin during CABG.26
Bivalirudin’s ability to inhibit clot-bound thrombin and
reduce endothelial proliferation might potentially protect
newly sutured grafts in CABG surgery.26 In addition, be-
cause there is no antidote for bivalirudin and its anticoagulant
effects are not reversed abruptly, anticoagulation can persist
for some time during the early postoperative phase, providing
further graft protection.26 Our study supports this idea,
whereby the long-term angiographic follow-up in 54 patients
showed only 4 of the LITA grafts that were originally patent
at intraoperative angiography to have occluded at follow-up.
This illustrates a long-term LITA patency rate of 93%, which
would indicate the use of bivalirudin to be safe in LITA anas-
tomosis. Thus far, this has been the only long-term angio-
graphic follow-up study of patients undergoing CABG with
bivalirudin without cardiopulmonary bypass.27 Moreover,
the extended period of postoperative anticoagulation appears
to provide protection from stent thrombosis until clopidogrel
administered immediately after the procedure becomes
therapeutic. Only 9 (15%) stents shows complications (7 in-
segment binary restenoses and 2 occlusions), of which 5The Journal of Thowere from the subset of 14 patients having had 20% or greater
residual stenosis at the stent insertion site (Table 3). Exclud-
ing these 5 stents with complications caused by technical
problems with insertion, only 4 (7%) stents showed problems
with the described anticoagulation and antiplatelet strategy.
Although the ideal strategy would be to administer clopidog-
rel before the procedure,24,25 we tried to overlap the effect of
bivalirudin and clopidogrel within the 2-hour period after
PCI25 by continuing the infusion of bivalirudin after admin-
istration of clopidogrel as long as possible until transfer to the
ICU. Our goal was to minimize the risk of stent thrombosis
with the least amount of postoperative bleeding. Still, 2 pa-
tients receiving bivalirudin were found to be coagulopathic
and required re-exploration with sternotomy. One patient
had received a combination of both intravenous heparin
and bivalirudin and the other had thromboelastogram studies
verifying ASA-related hyperresponsive platelet dysfunc-
tion.28 Although speculative, the use of 2 anticoagulants in
combination and a hyperresponse to ASA might have con-
tributed to these patient’s coagulopathies. After the one
case, our protocol was amended; heparin and bivalirudin
were no longer used in combination.
Simultaneous ICR is not without potential drawbacks and
limitations. Operative times are longer than those of conven-
tional CABG surgery because of the need to coordinate 2 pro-
cedures; however, this improves significantly with increased
experience. It also necessitates the use of aggressive perio-
perative antiplatelet therapy, thereby increasing the potential
for perioperative blood loss and the need for blood transfu-
sions. Indeed, mean 24-hour chest tube drainage was slightly
increased in our series compared with that seen with conven-
tional CABG (Table 4). However, the 3 patients requiring re-
exploration for bleeding largely account for this increased
drainage. Furthermore, only 9 (16%) patients inevitably re-
quired blood transfusions. Also, the inability to tolerate beat-
ing heart revascularization and the possible need to convert to
sternotomy is always a concern. In this series 4 (6.6%) of 60
patients required sternotomy for bleeding (2 patients) and
ventricular arrhythmias (2 patients), as previously discussed.
Finally, it must be emphasized that the early perceived ben-
efits of DESs have recently come into question, and their
long-term safety is still to be determined.29,30
In conclusion, robotically assisted simultaneous ICR is
a safe, reproducible, and feasible approach to multivessel
coronary artery disease in select patient populations. More-
over, bivalirudin is a safe and effective sole anticoagulant
for this procedure. Expertise in endoscopic and minimally in-
vasive cardiac surgical techniques, as well as a collaborative,
team-oriented approach among cardiac surgeons, interven-
tional cardiologists, and anesthesiologists, is imperative for
success.
Randomized prospective studies with long-term patient
follow-up comparing simultaneous ICR with conventional
CABG procedures or multivessel PCI will be necessary toracic and Cardiovascular Surgery c Volume 136, Number 3 707
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ETfurther evaluate the true effect of this technology on patient
care and to assess whether this therapeutic approach is asso-
ciated with similar long-term outcomes.
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